Blood glucose monitoring solutions provider LifeScan has launched a new version of its diabetes management mobile app OneTouch Reveal which now has new features.
OneTouch Reveal is designed to enable the wireless monitoring of blood sugar. Users will also be able to share the results with their healthcare team.
The new version comes with functionality to automatically identify recurring highs or lows in the blood sugar and alerts users on their smartphones.
In addition, the new OneTouch Reveal allows patients to set and track their personalised goals for blood glucose tests, carbohydrates logging and other daily activities.
They can also use the diabetes management tool to compare their 90-day average to the logged lab A1c in order to check the levels of their blood sugar over time.
The app is currently available for use in a total of 24 countries, including Belgium, Canada, France, Germany, India, the US, Italy, Ireland, Spain, the UAE, Poland and the UK.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Last month, LifeScan secured the European CE-Mark for the OneTouch Verio Reflect system with Blood Sugar Mentor. The company is planning for the commercial launch of the device in France this month, with an introduction to additional EMEA markets planned for next year.
Furthermore, LifeScan is seeking approvals for the OneTouch Verio Reflect system in the US and Canada.
The company said that the device can be synced with the OneTouch Reveal app for additional features such as Blood Sugar Mentor alerts and customisation of system settings from the app.
LifeScan was a division of Johnson and Johnson, which recently divested the company to private investment firm Platinum Equity for approximately $2.1bn.